‪#‎ChoiceBroking‬ ‪#‎Financial‬ Tips Morning Tea ‪#‎NATCOPHARMA‬ ‪#‎Buy‬ in the range of 544-547 for the ‪#‎Target‬ of 558 with the ‪#‎SL‬ of 538 ‪#‎INFY‬ #Buy in the range of 1063-1070 for the #Target of 1092 with the #SL of 1052

1. SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
DrugmajorNatcoPharmahasgotapprovalfromtheDrugsControllerGeneralofIndia(DCGI)tosellgenericversionofDaclatasvir,whichisusedfor
treatment of chronic hepatitis C. Natco Pharma said: "It is the first company in India to get approval for generic Daclatasvir Dihydrochloride
(Daclatasvir) tablets, 30 mg & 60 mg, from the Drugs Controller General (India)." Daclatasvir is the first-in-class NS5A inhibitor used in combination
with Sofosbuvir for the treatment of patients with chronic hepatitisC virus (HCV) genotype 3 infection. Natco said it will market generic Daclatasvir
underitsownbrand'NATDAC',andthroughitsstrategicpartnersinIndia.NatcowilllaunchimmediatelyinIndiaatRs6,000andRs4,000 forthe60
mgand30mgstrengths,respectively,forabottleof28tablets.
Technical Outlook: Ondaily chart, stockhasbeen continuously trading withits Higher Bottom formation. Moreover, stockhasbeen trading with
its 21 & 50 Day Moving average which shows that near to medium trend is up. In recent days, we have also observed appealing volume activity
along with rise inprice in the counter, which shows that graduallyincreasing buying activity. A momentum indicatorRSI reading is above 60 marks
with positive crossover, which point out for positive breath in the stock. so for trading perspective, one could Buy in the range of 544-547 for the
Targetof558 withtheSLof538.
NATCOPHARMA
INFY
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Morning Tea
15th Dec 2015
Buy in the range of 1063-1070 for the Target of 1092 with the SL of 1052
Buy in the range of 544-547 for the Target of 558 with the SL of 538
Country’s second largest software services firm Infosys Ltd on Monday said it has invested USD 3 million in WHOOP, Inc, an early stage company
offering a performance optimization system for elite professional sports teams. “It has made an investment of USD 3 million in WHOOP”, Infosys
saidin a filling to the Bombay Stock Exchange on December 14, 2015. The IT firm said that the all-cash transaction is expected tobe completed by
December 16, 2015. WHOOP offers a highly differentiated performance optimization and analytics solution that is of strategic importance to
Infosys in the professional team sports and connected wellness markets, it added. Through investment, Infosys has picked up a minority, not
exceeding 20 per cent of the outstanding share capital of the company, it said. WHOOP was originally incorporated on December 31, 2011 with
presenceintheUS.
Technical Outlook : Ondaily chart, stockhas formed Double Uglytype ofBottom pattern whichisbullishreversal indication.Furthermore, stock
has managed to close above its 21 & 200 Day Moving Average which shows that stock’s medium to long term trend is up. A momentum indicator
RSI reading is above 50 marks with positive crossover, which point out for positive breath in the stock. so for trading perspective, one could Buy in
therangeof1063-1070 fortheTargetof1092 withtheSLof1052.
U.S. stocks were relatively flat on Monday, as investors proceeded cautiously ahead of a likely interest rate hike by
the Federal Reserve at the completion of its two-day meeting later this week. The Federal Open Market Committee is
widely expected to approve its first rate hike in nine years when it concludes its December monetary policy meeting
on Wednesday. European stocks were higher on Monday, as all eyes were on the Federal Reserve's upcoming policy
decision this week.
Indian shares are likely to open in the red, though any losses will likely be capped and may be reversed later, amid
mixed trading in Asian markets and after Wall Street closed in the green overnight. Volumes are expected to be light,
however, as traders keep positions light going into the key two-day Federal Reserve meeting that will commence in
the US today.

2. SEBI Certified – Research Analyst www.choiceindia.com
Bulk Deal
Corporate Action / Result Calendar
SEBI Certified – Research Analyst www.choiceindia.com
Morning Tea
Corporate Action:
Jaiprakash Associates Limited; Annual General Meeting.
Result Calendar:
15th Dec 2015
Security in Ban
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Sr. No. Deal Date Script Code Security Name Client Name Deal Type Quantity Price
1 14/12/2015 534060 PMCFIN SEABIRD RETAILS PRIVATE LIMITED S 4161446 0.63
2 14/12/2015 533761 GPTINFRA PARAMVALUE INVESTMENTS B 548810 150.00
3 14/12/2015 531499 SYBLY VICHITRA TRAVELS PVT. LTD. S 500000 4.00
4 14/12/2015 530967 KYRALANDS INVENTURE GROWTH & SECURITIES LTD. S 400000 0.62
5 14/12/2015 530967 KYRALANDS BALUSAMY VELAYATHAM B 354030 0.63
6 14/12/2015 533761 GPTINFRA Rashmi Keyal S 244340 150.00
7 14/12/2015 533761 GPTINFRA Mahesh Keyal S 188760 150.00
8 14/12/2015 533761 GPTINFRA Ayush Keyal S 166900 150.00
9 14/12/2015 536672 VCU SOHNI DIPAK TANNA S 156000 26.00
10 14/12/2015 512301 CHMBBRW MANISHA NILESH KOTHARI S 72930 15.40
IBREALEST & UNITECH

3. SEBI Certified – Research Analyst www.choiceindia.com
Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
SEBI Certified – Research Analyst www.choiceindia.com
Research Team
Mr. Sumeet Bagadia Associate Director
Kunal Parmar Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Kapil Shah Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
15th Dec 2015
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website